Kjelsåsveien 168 B
167 articles with Nordic Nanovector
Nordic Nanovector ASA November 16, 2018: Increased Share Capital Following Exercise of Employee Share Options
A individual participant in Nordic Nanovector ASA's previous share option program, not being a primary insider, has exercised a total number of 300,000 options through exercise of a corresponding number of free-standing warrants. 185,421 of the options are exercised at a strike price of NOK 25 per share, and 114,579 of the options are exercised at a strike price of NOK 14.24 per share.
Nordic Nanovector ASA (OSE: NANO) announces its third quarter 2018 results today.
Nordic Nanovector ASA will announce its third quarter 2018 results on Tuesday, 6 November 2018.
Nordic Nanovector Announces First Patient Dosed in Archer-1 Trial of Betalutin® Plus Rituximab in Follicular Lymphoma
Nordic Nanovector ASA announces that the first patient has been dosed in the Archer-1 trial investigating Betalutin® (177Lu-satetraxetan-lilotomab) in combination with rituximab (RTX) in second-line follicular lymphoma (2L FL).
Nordic Nanovector: Promising Results from Preclinical Studies with a Novel CD37-targeted Alpha Therapy for B-cell Tumours to be Presented at ASH
Nordic Nanovector (OSE: NANO) announces that an abstract reporting promising results from a research collaboration to develop a novel CD37-targeting alpha therapy for B-cell malignancies has been published.
Nordic Nanovector Highlights Promising Clinical Results from Phase 1/2 Trial of Betalutin® in Relapsed/Refractory Indolent non-Hodgkin's Lymphoma
Overall response rates of 69% in Arm 4 and 64% in Arm 1 in relapsed/refractory follicular lymphoma patients
Nordic Nanovector Announces Opening of First US Site for PARADIGME Trial of Betalutin® in Third-line Follicular Lymphoma
Nordic Nanovector ASA announces that the first clinical site in the United States (in Long Beach, CA) for the pivotal PARADIGME trial has been initiated to enable enrolment of patients.
Nordic Nanovector's Betalutin® Receives Promising Innovative Medicine (PIM) Designation in the UK for the Treatment of Follicular Lymphoma
Nordic Nanovector ASA today announces that Betalutin® (177Lu-satetraxetan-lilotomab) has been granted a Promising Innovative Medicine (PIM) designation by the UK's Medicines and Healthcare Products Regulatory Agency (MHRA) for the treatment of patients with advanced relapsed/refractory follicular lymphoma (R/R FL).
Nordic Nanovector ASA announces it will present its results for the third quarter 2018 on Tuesday, 6 November 2018 (previously scheduled for Tuesday, 21 November), and will host a results presentation and webcast on the same day (details will be announced nearer the time).
Nordic Nanovector - Financial Calendar 2018 and 2019
Nordic Nanovector Presentations at the Annual Congress of the European Association of Nuclear Medicine (EANM)
Nordic Nanovector ASA announces that the Company and its collaborators will present data and analyses from its non-clinical and clinical studies with Betalutin® (177Lu-lilotomab satetraxetan) at the 32nd Annual Congress of the European Association of Nuclear Medicine (13-17 October 2018, Düsseldorf, Germany).
Nordic Nanovector: Abstracts of LYMRIT 37-01 Study With Betalutin® in NHL Patients and Other Studies Accepted for Poster Presentations at ASH
Nordic Nanovector ASA announces that an abstract reporting data from the Phase 1/2a LYMRIT 37-01 study investigating Betalutin® (177Lu-lilotomab satetraxetan) in patients with relapsed/refractory indolent non-Hodgkin's lymphoma (iNHL) has been accepted for a poster presentation at the 60th Annual Society of Hematology (ASH) Annual Meeting & Exposition (1-4 December 2018, San Diego, CA).
A participant in Nordic Nanovector ASA's (the "Company") (OSE:NANO) previous employee share option program, not being a primary insider, has exercised a total number of 30,832 options through exercise of a corresponding number of free-standing warrants.
Nordic Nanovector ASA announces its second quarter and first half 2018 results today. A presentation by the company's senior management team will take place today in Oslo at 08:30 CEST, see details below.
Nordic Nanovector ASA: Invitation to Second Quarter and First Half 2018 Results Presentation and Webcast
Nordic Nanovector ASA announces its second quarter and first half 2018 results on Wednesday, 22 August 2018.
Reference is made to the stock exchange notice published by Nordic Nanovector ASA on 3 July 2018 where the Company announced that the board of directors of the Company had resolved to increase the Company's share capital in connection with the exercise of RSUs.
Nordic Nanovector ASA: Increase of Share Capital/Mandatory Notification of Trade and Issuance of PSUs
Three of the board members of Nordic Nanovector ASA, Gisela Schwab, Joanna Horobin and Jean-Pierre Bizzari, have resolved to settle a total number of 6,035 RSUs that were issued to them in June 2017
Mr. Bravo brings more than 25 years' experience in the biopharmaceutical industry and a strong track record in leading and growing international biotech and pharmaceutical organisations.
Nordic Nanovector Announces Archer-1 Trial of Betalutin® plus Rituximab in 2L Follicular Lymphoma Approved to Start in Norway
Nordic Nanovector ASA has received approval from the Regional Committees for Medical and Health Research Ethics (REK) in Norway with regard to the Clinical Trial Application (CTA) for the Archer-1 Phase 1b trial with Betalutin® (177Lu-satetraxetan-lilotomab) in combination with rituximab in second-line follicular lymphoma patients (2L FL).
Nordic Nanovector Announces Betalutin® has been Granted Fast Track Designation in the US for Follicular Lymphoma
Treatment of patients with relapsed or refractory follicular lymphoma (FL) after at least 2 prior systemic therapies.